Lineage Cell Therapeutics (LCTX) Non-Current Assets (2010 - 2026)

Lineage Cell Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $53.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 13.6% year-over-year to $53.4 million; the trailing twelve-month figure through Mar 2026 stood at $201.1 million (down 19.09% YoY), and the FY2025 full-year result was $53.4 million, down 14.13% from the prior year.
• Non-Current Assets for Q1 2026 stood at $53.4 million, roughly flat from $53.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $63.6 million in Q1 2023, with the low at $5.7 million in Q4 2022.
• Historically, Non-Current Assets has averaged $56.3 million across 5 years, with a median of $62.2 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Assets surged 1003.08% — and 2025, when it retreated 24.77%.
• Lineage Cell Therapeutics' Non-Current Assets stood at $5.7 million in 2022, then surged by 1003.08% to $62.6 million in 2023, then fell by 0.57% to $62.2 million in 2024, then slipped by 14.13% to $53.4 million in 2025, then decreased by 0.11% to $53.4 million in 2026.
• The last three Non-Current Assets figures came in at $53.4 million (Q1 2026), $53.4 million (Q4 2025), and $47.4 million (Q3 2025), per Business Quant data.